4 completed, 1 terminated, 1 unknown, 1 withdrawn. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Unknown 1 |
Follow RNA, Messenger: new trials by email Literature Review of RNA, Messenger trials Research Report on RNA, Messenger
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2 - Influenza, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1162 | 2025-01-06 | 2026-06-09 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients TriMix_100, TriMix_300, 600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA) - HIV-infection | Phase 1 | Completed | Judit Pich Martínez | 21 | 2015-06-01 | 2025-08-22 |
| A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection - HIV-1 Infection, HIV Infections | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 15 | 2009-08-01 | 2016-03-08 |
| Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients autologous dendritic cells electroporated with mRNA - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Radboud University Medical Center | 23 | 2009-06-01 | 2018-12-07 |
| Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients mRNA, GM-CSF s.c. - Malignant Melanoma | Phase 1 / Phase 2 | Completed | University Hospital Tuebingen | 20 | 2004-07-01 | 2007-04-19 |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy Peptide vaccine, Montanide ISA-51, Granulocyte macrophage colony stimulating factor (GM-CSF) - Recurrent Prostate Cancer | Phase 1 / Phase 2 | Unknown | University Hospital Tuebingen | 36 | 2004-04-01 | 2017-08-17 |
Acquired Immunodeficiency Syndrome (1) · HIV Infections (1) · Hemangiosarcoma (1) · Influenza, Human (1) · Melanoma (1) · Prostatic Neoplasms (1) · Uveal Melanoma (1)
University Hospital Tuebingen (2) · Judit Pich Martínez (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Radboud University Medical Center (1) · Sanofi Pasteur, a Sanofi Company (1)
United States (2) · Australia (1) · Germany (1) · Netherlands (1) · Spain (1)
Arnulf Stenzl, Prof. (1) · Claus Garbe, Prof. Dr. (1) · Cornelis JA Punt, prof.MD (1) · Rajesh Gandhi, MD (1) · Vinod Ravi, MD (1)
2014 (1), R01AI066992 (1)